Clinical Trials Logo

EGFR Mutation clinical trials

View clinical trials related to EGFR Mutation.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT03486496 Not yet recruiting - Lung Adenocarcinoma Clinical Trials

Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation

Geber
Start date: June 5, 2018
Phase: Phase 2
Study type: Interventional

Rationale: Advanced non-small-cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations (del19 or L858R) show an impressive progression-free survival between 9 and 11 months when treated with gefitinib. Combination of gefitinib and berberine could improve efficacy in lung cancer with EGFR mutation in vivo and vitro. The investigators hypothesize that progression-free survival could be improved by combination of gefitinib and berberine.

NCT ID: NCT02226757 Not yet recruiting - NSCLC Clinical Trials

Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients

Start date: August 2014
Phase: Phase 2
Study type: Interventional

This study is a pilot study in EGFR-mutated NSCLC patients who have progressed on standard-dose TKIs. Tumor biopsies will be evaluated for HER2-expression. In case of HER2 expression, patients can participate in the trial after obtaining informed consent. Patients will be treated with weekly paclitaxel-trastuzumab.